Form 4: Edwards Lifesciences CFO Vests Performance Shares

CFO Scott Ullem acquired 19,830 shares through performance-based vesting, achieving 167.70% of target goals.

Summary

• Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences, vested 19,830 shares of common stock on May 11, 2026.
• The vesting was based on performance rights granted in May 2023, which achieved a 167.70% payout level based on three-year performance metrics.
• A total of 11,004 shares were withheld by the company to satisfy tax withholding obligations at a price of $79.96 per share.
• Following the transaction, Ullem directly owns 46,740 shares and maintains a significant indirect holding of 266,318 shares through a trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as positive due to the high performance achievement (167.7%) which reflects well on management's ability to hit aggressive targets, despite the routine nature of the filing.

Positives

• Performance-based vesting reached 167.70% of the target, indicating the company significantly exceeded its internal performance benchmarks over the three-year period.
• The CFO maintains a very high level of indirect ownership (266,318 shares), suggesting strong long-term alignment with shareholder interests.

Negatives

• The disposal of 11,004 shares represents a 55% reduction of the newly vested shares, though this was specifically for tax obligations.

Risks

• Executive compensation is heavily tied to performance metrics which may fluctuate in future periods.
• Market volatility could impact the value of the remaining 313,058 total shares held by the CFO.

Future Outlook

The vesting of these shares concludes a three-year performance cycle; future equity-based compensation will continue to depend on the company meeting specific governance and financial targets set by the Board.

Management Comments

• The Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026.

Industry Context

StockSavvy.ai notes that a 167.70% performance achievement is robust for the medical technology sector, suggesting Edwards Lifesciences outperformed its peer group or internal growth targets during the 2023-2026 cycle.

Comparison to Industry Standards

• The 167.7% payout is at the higher end of typical executive performance plans, which usually cap at 150% to 200%.
• Compared to peers like Medtronic or Boston Scientific, this level of achievement suggests superior execution on specific internal KPIs.

Corporate Governance

Related Party Transactions

• Shares held by a trust for which the reporting person likely serves as a trustee or beneficiary.

Stakeholder Impact

• Shareholders may be encouraged by the high performance achievement metrics.
• The CFO remains heavily invested in the company, providing stability for creditors and investors.

Next Steps

• Monitor subsequent Form 4 filings for other executives to see if similar high performance achievement levels were reached across the leadership team.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation. While the high performance achievement is a positive sign, it does not fundamentally change the investment thesis outside of confirming management is meeting its targets.

Keywords

Edwards Lifesciences, EW, Insider Trading, Scott Ullem, Executive Compensation, Performance Rights, Stock Vesting, Medical Devices